Analysts expect Sophiris Bio Inc (NASDAQ:SPHS) to announce earnings per share (EPS) of ($0.09) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sophiris Bio’s earnings, with estimates ranging from ($0.11) to ($0.08). Sophiris Bio posted earnings per share of ($0.13) during the same quarter last year, which would indicate a positive year over year growth rate of 30.8%. The firm is expected to report its next quarterly earnings report on Monday, May 15th.
On average, analysts expect that Sophiris Bio will report full year earnings of ($0.38) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.33). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.59) to ($0.33). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last posted its earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.09.
SPHS has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Sophiris Bio in a report on Tuesday, March 28th. Rodman & Renshaw restated a “buy” rating and set a $6.00 target price on shares of Sophiris Bio in a report on Tuesday, March 28th. Piper Jaffray Companies restated an “overweight” rating and set a $7.00 target price on shares of Sophiris Bio in a report on Thursday, April 6th. Finally, Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a report on Saturday, March 25th. Six equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $6.33.
TRADEMARK VIOLATION WARNING: “-$0.09 Earnings Per Share Expected for Sophiris Bio Inc (SPHS) This Quarter” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/05/19/0-09-earnings-per-share-expected-for-sophiris-bio-inc-sphs-this-quarter-updated.html.
Sophiris Bio (NASDAQ:SPHS) traded up 1.107% during midday trading on Tuesday, hitting $2.558. The company had a trading volume of 188,311 shares. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $2.74. Sophiris Bio has a 1-year low of $0.80 and a 1-year high of $8.55. The firm’s market capitalization is $77.02 million.
A hedge fund recently bought a new stake in Sophiris Bio stock. Oxford Asset Management bought a new stake in Sophiris Bio Inc (NASDAQ:SPHS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 175,198 shares of the biopharmaceutical company’s stock, valued at approximately $491,000. Oxford Asset Management owned approximately 0.58% of Sophiris Bio as of its most recent filing with the SEC. Institutional investors own 5.99% of the company’s stock.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.